Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction Dual antiplatelet therapy (DAPT) after coronary stenting prolongs survival by preventing both in-stent thrombosis and other cardiovascular atherothrombotic events. Patients with peripheral artery disease (PAD) typically have a heavy burden of unrevascularized coronary artery disease and also stand to benefit from increased atherothrombotic protection with DAPT. The potential benefit of DAPT compared to aspirin alone in patients with PAD is not well described. Methods We identified all patients undergoing an initial elective lower extremity revascularization (bypass or endovascular) from 2003 to 2016 in the Vascular Quality Initiative (VQI) registry discharged on aspirin or aspirin plus a thenopyradine anti-platelet agent (dual anti-platelet therapy (DAPT)). We first estimated models predicting the likelihood of receiving DAPT and then used inverse probability weighting to account for baseline differences in the likelihood to receive DAPT and compared late survival. For sensitivity analysis we also performed Cox proportion hazard modeling on the unweighted cohorts and generated adjusted survival curves. Results We identified 57,041 patients undergoing lower extremity revascularization (28% bypass). Of 15,985 bypasses (69% for critical limb ischemia (CLI)) 38% were discharged on DAPT. Of 41,056 endovascular interventions (39% for CLI) 69% were discharged on DAPT. Analyses using inverse probability weighting demonstrated small survival benefits to DAPT at one-year for bypass (93% vs. 92%, P = .001) and endovascular interventions (93% vs. 92%, P = .005) that was sustained through five-years of follow-up (bypass: 80% vs. 78%, P = .004; Endovascular: 76% vs. 73%, P = .002). When stratified by severity of PAD, DAPT had a survival benefit for patients with CLI undergoing bypass (five-year: 70% vs. 66%, P = .04) and endovascular intervention (five-year: 71% vs. 67%, P = .01) but not for patients with claudication (bypass: 89% vs. 88%, P = .36; endovascular: 87% vs. 85%, P = .46). The protective effect of DAPT was similar when using Cox Proportional hazard models after bypass (HR 0.81, 95% CI 0.72 – 0.90) and endovascular intervention (HR 0.89, 0.83 – 0.95). Conclusion Dual antiplatelet therapy at time of discharge was associated with prolonged survival for patients with CLI undergoing lower extremity revascularization but not for those with claudication. Further research is needed to quantify the risks associated with DAPT and to identify subgroups at increased risk of thrombotic and bleeding complications in order to guide medical management of patients with PAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191 · cited 1×
“[9–15] The major consensus guidelines for PAD suggest using mono antiplatelet therapy in PAD but state that the data either for or against the use of DAPT in this population are too limited to make strong recommendations.[1, 9, 10, 16] There has been an attempt to update the international TASC guidelines but disagreem…”
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999 · cited 1×
“[15] This is further supported by evidence that medically managed patients with acute coronary syndrome had fewer subsequent MIs on DAPT compared to aspirin and placebo in the CURE trial and lower composite stroke, MI, and cardiovascular death for patients with a history of MI one to three years prior, in the Pegasus-…”
ResultTwelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928 · cited 2×
“[10] The benefit to DAPT in this setting is thought to not only be from prevention of stent thrombosis but also from a decrease in atherothrombotic events in coronary vessels outside of the stented artery.[15] This is further supported by evidence that medically managed patients with acute coronary syndrome had fewer…”
ResultSmith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759 · cited 2×
“[9–15] The major consensus guidelines for PAD suggest using mono antiplatelet therapy in PAD but state that the data either for or against the use of DAPT in this population are too limited to make strong recommendations.[1, 9, 10, 16] There has been an attempt to update the international TASC guidelines but disagreem…”
BackgroundOne-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382 · cited 1×
“[1–3] Individuals with peripheral artery disease (PAD), referring to arterial vascular disease of the extremities, have the greatest risk of experiencing cardiovascular death and myocardial infarction when compared to those with coronary artery disease or cerebrovascular disease alone.[4, 5] PAD usually signals more s…”
BackgroundBelch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Yeh, R. W., Secemsky, E. A., Kereiakes, D. J., Normand, S.-L. T., Gershlick, A. H., Cohen, D. J., Spertus, J. A., Steg, P. G., Cutlip, D. E., Rinaldi, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.3775 · Cited by 934
Anderson, J. L., Halperin, J. L., Albert, N., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Guyton, R. A., Hochman, J. S., Kovacs, R. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.004 · Cited by 664
Cited by
Global Vascular Guidelines on the management of chronic limb-threatening ischemia.
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.02.016 · Cited by 2,015
Global vascular guidelines on the management of chronic limb-threatening ischemia
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2019.05.006 · Cited by 1,582
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Self-citationGornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Self-citation
Metadata
- Authors
- Soden, P. A., Zettervall, S. L., Ultee, K. H. J., Landon, B. E., O'Malley, A. J., Goodney, P. P., DeMartino, R. R., Arya, S., & Schermerhorn, M. L.
- Venue
- Journal of Vascular Surgery
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 64
- Issue
- 6
- Pages
- 1633-1644.e1
- ISSN
- 0741-5214 (ISSN-L)
- OpenAlex
- W2510098524
- Cited by
- 59
- References
- 12
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.